Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

shankar besta

  • Home
  • Author: shankar besta

Houlihan Lokey and Lazard top M&A financial advisers in automotive sector during Q1 2024, reveals GlobalData

Houlihan Lokey and Lazard were the top mergers and acquisitions (M&A) financial advisers in the automotive sector during the first quarter (Q1) of 2024 by value and volume, respectively, according to the latest financial advisers league table by GlobalData, a leading data and analytics company. An analysis of GlobalData’s Deals Database reveals that Houlihan Lokey […]
Read more

Biohaven’s Taldefgrobep alfa could target broad SMA patient population, says GlobalData

At the American Academy of Neurology (AAN) 2024 Annual Meeting, Biohaven presented its Phase III RESILIENT (NCT05337553) trial design, which investigates the efficacy and safety of taldefgrobep alfa in patients with spinal muscular atrophy (SMA). Taldefgrobep alfa is a myostatin inhibitor in development as an adjunctive therapy alongside marketed therapies to offer symptomatic relief to […]
Read more

Oligonucleotides and mRNA vaccines dominate in strategic alliances for RNA-therapies in major APAC countries, says GlobalData

RNA-based therapies have already proven and will continue to play an integral role in the development of novel therapeutic agents for diseases in the future. Against this backdrop, biopharmaceutical companies based in the major Asia-Pacific (APAC) countries (Australia, China, Japan, and South Korea) entered into significant partnerships to develop RNA-based therapies in the last five […]
Read more

Radius Pharmaceuticals’ Tymlos will have to face highly competitive osteoporosis market despite positive results, says GlobalData

Radius Pharmaceuticals unveiled real-world evidence at the recently held World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases, demonstrating increased efficacy of Tymlos (abaloparatide) therapy in reducing hip and non-vertebral fractures compared to teriparatide in women aged 50 years and older. Despite positive results, Tymlos will have to face a highly competitive osteoporosis market, according to […]
Read more

Generative AI advances to reshape healthcare, says GlobalData

Generative artificial intelligence (genAI) is rapidly gaining traction in the healthcare and pharmaceutical domains, marking substantial advancements. By not only tackling high costs but also elevating patient experiences by enhancing efficiency and outcomes, this technology stands ready to revolutionize many aspects of the industry, says GlobalData, a leading data and analytics company. Saurabh Daga, Associate […]
Read more

Morgan Stanley and Lazard top M&A financial advisers in construction sector during Q1 2024, reveals GlobalData

Morgan Stanley and Lazard were the top mergers and acquisitions (M&A) financial advisers in the construction sector during the first quarter (Q1) of 2024 by value and volume, respectively, according to the latest financial advisers league table by GlobalData,  a leading data and analytics company. An analysis of GlobalData’s Deals Database reveals that Morgan Stanley […]
Read more

Paul, Weiss, Rifkind, Wharton & Garrison and Kirkland & Ellis top M&A legal advisers in construction sector during Q1 2024, reveals GlobalData

Paul, Weiss, Rifkind, Wharton & Garrison and Kirkland & Ellis were the top mergers and acquisitions (M&A) legal advisers in the construction sector during the first quarter (Q1) of 2024 by value and volume, respectively, according to the latest legal advisers league table by GlobalData, a leading data and analytics company. An analysis of GlobalData’s […]
Read more

Cocktail culture can draw benefits, but faces challenges from Gen Z, says GlobalData

The ongoing rise in popularity of cocktails, in traditional hand-mixed as well as ready-to-drink forms, is benefitting from the emergence of Generation Z into the alcohol market. However, cocktail culture risks stagnation if overly fixated on nostalgic themes. Gen Z’s inclination towards quality over quantity, demanding innovation and relevance in their drinking experiences, is shaping […]
Read more

APPLAUSE-IgAN trial interim analysis highlights Novartis’ potential to differentiate in IgAN space, says GlobalData

At this year’s World Congress of Nephrology, positive results were presented from Novartis’s pre-specified interim analysis of the Phase III APPLAUSE-IgAN clinical trial. According to the analysis, the use of Fabhalta (iptacopan) was shown to reduce proteinuria in patients with immunoglobulin A (IgA) nephropathy (IgAN) compared to placebo. The drug potentially fills an unmet need […]
Read more
1 … 78 79 80 81 82 … 136